The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant interest within the British Isles, prompting a notable shift in hormone trends. Access these compounds remains a complex landscape, with public healthcare system coverage currently limited and private clinics offering prescriptions at a premium . C